Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Latest News

Market capUnder $1B
All Over $50MOver $300MOver $2BOver $10B
All Under $1BUnder $10BUnder $100BUnder $500B
SectorsAll
Filter by sector
Friday, October 16, 2026· 2298 stock ideas· 217 writers·
17,149 views· 7,918 clicks

From X

@StableBread

Fajasy on X

Even if the AI model Nubeva Technologies $NBVAF (TSXV: $NBVA) is training to read malware binaries (compiled programs) works, six risks could keep it from paying off: → Labs closing the gap: OpenAI’s GPT-6 Astra nearly doubled GPT-5.6-sol’s score on SRE-Bench, a Columbia University-led test of AI models on reading binaries, within a month of SRE-Bench’s release, and Anthropic says its Claude Mythos Preview model can already reconstruct plausible source code from stripped binaries. The better the labs’ own models get at reading hard binaries, the less they need to pay for outside labels. → Big tech building in-house: Microsoft’s $MSFT Project Ire reverse engineers software files on its own to decide whether they’re malicious. Ire caught only about a quarter of the malware among nearly 4,000 hard-to-classify files in a test Microsoft described in August 2025. But in June 2026, Microsoft said Ire flagged a new malware sample that most major security products, including CrowdStrike’s $CRWD and SentinelOne’s $S, still missed. Google $GOOGL already owns VirusTotal and Mandiant, so the likelier customers are labs that don’t own a malware-scanning site or an incident-response firm already, like OpenAI and Anthropic. → Paid like a contractor: Data labeling companies (firms that turn experts’ knowledge into training data for AI labs) pay 60-70% of what they bill to their contractors, and Scale AI is already recruiting its own malware analysts. So a data labeling company could pay Nubeva by the hour or task, or hire analysts itself, instead of licensing the model or buying the company. → Selling labels teaches the buyer: Every binary Nubeva labels helps the buyer’s model learn the same skill, the reason CEO Randy Chou gave for not patenting how Nubeva reads binaries. So each sale could shrink the edge Nubeva is selling. → Cash and compute: Chou gave no cost for running “hundreds and thousands” of AI agents on a private model. For reference, Nubeva spent $714,772 on R&D in FY2026, equal to 28.7% of its $2.49M in cash as of April 30, 2026. → Missed targets: Nubeva’s AI decryptor builder missed four targets starting in August 2023, so “days and weeks” (Chou’s timeline for the model) is a target, not a result just yet. So even with a working model, Nubeva still has to (1) sign a contract before the labs can read the hardest binaries themselves, (2) get paid for its model and engineers instead of by the hour or task, and (3) fund the training without draining its cash.

Investor Letters

All letters

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps
CUE · short

Cue Biopharma

Cue Biopharma faces a deteriorating balance sheet, recurring operating losses, ATM dilution and PIPE-investor selling pressure.

CUE $130M
Value Investors Club 3 clicks

Have a source we’re missing? Send your pick

Recent recaps

Latest recap

Thursday, October 15 61 stock ideas
  • Is The Market Turning The Page? WHAT ARE WE DOING? “Contrarians At The Gate”
  • Breaking: The Offshore Monopoly Is Legal Now! Cannibal Stocks
Read the recap

All recaps

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 49 of 231

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick